Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs XERS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XERS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

XERS Overall Winner 6-Pillar Tally: LCTX 1 – 5 XERS Matrix Metrics: LCTX 6 – 4 XERS

As of Nov 19, 2026, Xeris Biopharma Holdings, Inc. (XERS) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas XERS carries 33.8/100 (SELL) at $16.62 (62.3x Forward P/E, 12.7% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. XERS 33.8/100 SELL), XERS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.7% vs. -280.3% operating margin) and revenue trajectory (+44.2% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile XERS trades in a Markup technical trend (SURGE options phase, RSI 79.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs XERS
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
XERS NASDAQ Head-to-Head Winner
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.62
-2.18% 1D
Market Cap $3.1B
TTM Revenue $368M
Forward P/E 62.3x
Beta / 30D Vol -0.03β · 104% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (22.2% over 20 days), RSI 80
RSI-14: 79.8 · SMA20: $13.54 · SMA50: $11.10

6-Pillar Scorecard Institutional Category Breakdown (LCTX 1 – 5 XERS)

Columns: Metric · LCTX · XERS
1. Valuation Multiples LCTX
Forward P/E 30.7x 62.3x
Trailing P/E 30.7x 85.5x
PEG Ratio 10.64x N/M
EV / Revenue 16.3x 8.7x
2. Growth & Scale XERS
Revenue Growth (YoY) -61.0% +44.2%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $11M $368M
Market Cap $212.1M $3.1B
3. Profitability & Quality XERS
Gross Margin -95.0% 87.4%
Operating Margin -280.3% 12.7%
Net Profit Margin 16.2% -1.8%
Return on Equity (ROE) 4.3% -27.1%
4. Balance Sheet & Cash Flow XERS
Cash Generation (TTM) -$24M $73M
Cash Flow Margin N/A 19.7%
Net Cash / Leverage $35M Net Cash $95M Net Debt (4.63x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XERS
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 896.2% (100th %ile) 51.9% (12th %ile)
Put/Call OI Skew 1.10x (Balanced) 0.09x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat XERS
OpEx & R&D Intensity N/A 74.7% of Rev ($275M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (6) vs XERS (4)
Institutional Metric LCTX XERS Criterion Row Edge
Market Capitalization
Scale
$212.1M $3.1B Larger Scale XERS
Trailing P/E Ratio
Valuation
30.7x 85.5x Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x 62.3x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% +44.2% Higher Growth XERS
Operating Margin (TTM)
Profitability
-280.3% 12.7% Higher Margin XERS
Net Profit Margin
Profitability
16.2% -1.8% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -27.1% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 94% ($5–$17) Stronger Trend XERS
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol -0.03β · 104% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $368M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · 8.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) $73M ($95M Net Debt (4.63x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XERS +67.92 pp
LCTX: -13.82% · XERS: +54.1%
3M Horizon XERS +115.1 pp
LCTX: -24.07% · XERS: +91.03%
6M Horizon XERS +198.38 pp
LCTX: -37.88% · XERS: +160.5%
1Y Horizon XERS +188.42 pp
LCTX: -53.67% · XERS: +134.75%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue XERS Revenue LCTX Op. Margin XERS Op. Margin Margin Leader
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $20M -1448.4% -414.5% XERS
FY2021 $0M $50M -1133.6% -232.2% XERS
FY2022 $10M $110M -153.2% -74.3% XERS
FY2023 $10M $160M -276.5% -26.8% XERS
FY2024 $10M $200M -226.1% -16.6% XERS
FY2025 $10M $290M -251.6% 8.5% XERS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XERS SURGE
5d in phase · OBV ACCUMULATION
Current IV 51.9%
IV Percentile 12th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact XERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $16.60 · IV 60.5%

XERS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,660)

Compare $1,660 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 60.5% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $15 / $14 Bull Put Spread

Sell 3x $15P · Buy 3x $14P · 29d

Net Entry $138 Credit
Max Credit / Yield +$138 (+85.2% RoM)
Max Risk / Buffer -12.4% Cushion ($162 Mgn)
5d Edge & Liquidity 70% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $17 / $15 Bear Put Spread

Buy 2x $17P · Sell 2x $15P · 29d

Net Entry $74 Debit
T+5d @ -5% Drop +$43 (+59%)
Max Risk / Buffer $74 Capped
5d Edge & Liquidity 1.4x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XERS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.1B market capitalization and 12.7% operating margin.
OpEx & R&D Reinvestment 74.7% of Rev ($275M)
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs XERS Key Questions & Quantitative Answers

As of Nov 19, 2026, Xeris Biopharma Holdings, Inc. (XERS) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas XERS carries 33.8/100 (SELL) at $16.62 (62.3x Forward P/E, 12.7% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. XERS 33.8/100 SELL), XERS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.7% vs. -280.3% operating margin) and revenue trajectory (+44.2% vs. -61.0% YoY). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile XERS trades in a Markup technical trend (SURGE options phase, RSI 79.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XERS leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with XERS at +44.2% YoY revenue growth and N/A YoY earnings growth on $368M TTM revenue (87.4% gross margin, 12.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while XERS shifted +1350.0%. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus 74.7% of Rev ($275M) (0 disclosures) for XERS.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas XERS trades at 62.3x Forward P/E, 85.5x Trailing P/E, N/M PEG, and 8.7x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus XERS (-27.1% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, XERS carries 51.9% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (-0.03β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.